Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 2/20 | 0.42 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
| ▸ | PGK2 | P07205 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29755971 | 1.00 | P2RX7 (0.50) | P2RX7MAOBTAS2R14SYKGLS | |
| SCHEMBL31645933 | 0.84 | MAOB (0.55) | P2RX7MAOBTAS2R14SYKGLS | |
| SCHEMBL2312720 | 0.84 | MAOB (0.55) | P2RX7MAOBTAS2R14SYKGLS | |
| SCHEMBL26046016 | 0.84 | P2RX7 (0.49) | P2RX7MAOBTAS2R14GLSADAMTS4 | |
| SCHEMBL4495296 | 0.80 | AKR1B1 (0.48) | KDM4ESMN1; SMN2PGK1PGK2 | |
| SCHEMBL31646435 | 0.80 | P2RX7 (0.49) | P2RX7MAOBTAS2R14SYKKDM4E | |
| SCHEMBL534133 | 0.78 | SYK (0.47) | P2RX7MAOBSYKCYP2C19SMN1; SMN2 | |
| SCHEMBL30864787 | 0.78 | SYK (0.47) | P2RX7MAOBSYKCYP2C19SMN1; SMN2 | |
| SCHEMBL2373934 | 0.78 | P2RX7 (0.43) | P2RX7MAOBTAS2R14SYKADAMTS4 | |
| SCHEMBL30156698 | 0.77 | P2RX7 (0.47) | P2RX7MAOBTAS2R14GLSMBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20240382488-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-11-21 | — | — | US | disclosed |
| US-20240317752-A1 | 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-09-26 | — | — | US | disclosed |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230087342-A1 | AZEPANE DERIVATIVE | NIPPON CHEMIPHAR CO., LTD. (JP) | 2023-03-23 | — | — | US | disclosed |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| WO-2022212326-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2015056180-A1 | INDOLINE DERIVATIVES AS INHIBITORS OF PERK | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-04-23 | — | — | WO | disclosed |
| EP-2549868-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-01-07 | — | — | EP | disclosed |
| CN-104114543-A | Therapeutically active compounds and methods of use thereof | AGIOS PHARMACEUTICALS INC | 2014-10-22 | — | — | CN | disclosed |
| CN-102917588-B | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2014-10-08 | — | — | CN | disclosed |
| US-8598156-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-12-03 | — | — | US | disclosed |
| CN-102119029-B | 1, 5-diphenyl-pyrrolidin-2-one compounds as CB-1 ligands | LILLY CO ELI | 2013-03-13 | — | — | CN | disclosed |
| EP-2549868-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| WO-2011119663-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | P2RX7 3982/4885MAOB 3872/4885TAS2R14 2137/4885 |
| US-20240382488-A1 | NEK7 INHIBITORS | NEK7, NEK11, NEK2 | P2RX7 472/4885MAOB 1758/4885TAS2R14 4272/4885 |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | P2RX7 3466/4885MAOB 2391/4885TAS2R14 4109/4885 |
| US-20240317752-A1 | 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES | TYMP, DPYD, PNP | P2RX7 95/4885MAOB 446/4885TAS2R14 4174/4885 |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | P2RX7 3466/4885MAOB 2391/4885TAS2R14 4109/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | P2RX7 1935/4885MAOB 2531/4885TAS2R14 1659/4885 |
| US-20230087342-A1 | AZEPANE DERIVATIVE | ADCY10, AZI2, PRMT1 | P2RX7 1949/4885MAOB 714/4885TAS2R14 698/4885 |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | P2RX7 1103/4885MAOB 2743/4885TAS2R14 3823/4885 |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK4, IRAK2, IRAK3 | P2RX7 4079/4885MAOB 3579/4885TAS2R14 4443/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | P2RX7 1103/4885MAOB 2743/4885TAS2R14 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.